No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

GALEN regimen, Phase 2 trial

byKathleen Lau

December 31, 2021

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

RELATED REPORTS

2 Minute Medicine Rewind September 7, 2026

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

Tags: #cancer advanced follicular lymphoma advanced lymphoma blood blood cancer cancer chemo-free chemotherapy complete response rate CRR efficacy outcomes febrile neutropenia FL follicular lymphoma GALEN hematology high tumor burden high tumour burden induction infection infusion-related reaction IWG 1999 Criteria lenalidomide maintenance neutropenia Obinutuzumab oncology os overall survival pfs previously untreated lymphoma progression-free survival skin reaction survival outcomes untreated lymphoma

Moderate caffeine intake may not be associated with cardiometabolic pregnancy complications

RelatedReports

Long-term outcomes for off-pump and on-pump CABG are similar

Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026

Nivolumab may be effective in platinum-resistant ovarian cancer

Surgery

Perioperative toripalimab improves event-free survival in non-small cell lung cancer

August 9, 2026

Influenza vaccine not associated with increased risk of epilepsy in children

Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

2 Minute Medicine Rewind January 3, 2022

Kangaroo mother care linked to better neonatal outcomes

Mediterranean diet and mindfulness-strategies reduced risk of low-birth-weight newborns

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

GALEN regimen, Phase 2 trial

2 Minute Medicine Rewind September 7, 2026

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

Moderate caffeine intake may not be associated with cardiometabolic pregnancy complications

Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

RelatedReports

2 Minute Medicine Rewind September 7, 2026

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

Perioperative toripalimab improves event-free survival in non-small cell lung cancer

Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

2 Minute Medicine Rewind January 3, 2022

Mediterranean diet and mindfulness-strategies reduced risk of low-birth-weight newborns

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits